Skip to main content
Evidence Snapshot

Fibroblast growth factor receptor 2

CHEMBL4142 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4142
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor receptor 2 as ChEMBL target CHEMBL4142, mapped to UniProt P21802. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4142
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P21802
Fibroblast growth factor receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Fibroblast growth factor receptor 2 matters

As of 2026-09-14

Fibroblast growth factor receptor 2 is reviewed as Fibroblast growth factor receptor 2 (UniProt P21802); Fibroblast growth factor receptor 2 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 23 approved drugs, 4685 compounds, and 724 assays, with lead potency reaching pChEMBL 10.0.

Disease context
neoplasm

Fibroblast growth factor receptor 2 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BEMARITUZUMAB, E-7090, FGFR INHIBITOR DEBIO 1347.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BEMARITUZUMAB, E-7090, FGFR INHIBITOR DEBIO 1347, HMPL-453. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 9 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 23 approved drugs, 4685 compounds, and 724 assays for this target. The dominant activity type is IC50. CHEMBL5173892 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL5173892 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
23 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Fibroblast growth factor receptor 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21802, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4685
Total Compounds
724
Total Assays
23
Approved Drugs
IC50: 4652.0, KI: 5.0, EC50: 4.0, KD: 171.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5173892
 10.0 IC50 —
No preferred name
CHEMBL5589978
 9.9 IC50 —
No preferred name
CHEMBL6043032
 9.9 IC50 —
No preferred name
CHEMBL4870179
 9.8 IC50 —
No preferred name
CHEMBL3798625
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
FUTIBATINIB
CHEMBL3701238
 2022
INFIGRATINIB
CHEMBL1852688
 2021
INFIGRATINIB PHOSPHATE
CHEMBL1834657
 2021
PEMIGATINIB
CHEMBL4297522
 2020
ERDAFITINIB
CHEMBL3545376
 2019
FEDRATINIB
CHEMBL1287853
 2019
BRIGATINIB
CHEMBL3545311
 2017
LENVATINIB
CHEMBL1289601
 2015
NINTEDANIB ESYLATE
CHEMBL3039504
 2014
NINTEDANIB
CHEMBL502835
 2014
CERITINIB
CHEMBL2403108
 2014
IBRUTINIB
CHEMBL1873475
 2013
PONATINIB
CHEMBL1171837
 2012
AXITINIB
CHEMBL1289926
 2012
PAZOPANIB
CHEMBL477772
 2009
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4142